You are here

P&T® Journal contents for January 2005


Health Care & Law
If another agency, similar to the FDA, were created to handle postmarketing surveillance of drugs, would we be able to avoid recalls?
Robert I. Field, JD, MPH, PhD
The authors present the example of a triptan case study to help formulary decision-makers evaluate the cost-effectiveness of drugs within a category.
Mei-Jen Ho, PharmD, Vijay N. Joish, PhD, and Joseph E. Biskupiak, PhD, MBA
Meeting Highlights
Dr. Prescott reviews the use of azithromycin microspheres for acute exacerbation of chronic bronchitis; moxifloxacin for intra-abdominal infection; oseltamivir for reducing the risk of pneumonia; anidulafungin for HIV-negative patients with esophageal candidiasis; enfuvirtide; tipranavir and combination therapies for HIV infection; and peginterferon alfa-2a/ribavirin for HIV/hepatitis C co-infection.
Lawrence M. Prescott, PhD
Meeting Highlights
The author summarizes the benefits of an extended-release niacin/statin combination to slow atherosclerosis; telmisartan for hypertensive patients with the metabolic syndrome; a glucose–insulin infusion for acute myocardial infarction; tilarginine; a nitrate/diuretic for African-Americans with heart failure; isotope versus vasodilator therapy; rimonabant for weight loss; atorvastatin to delay Alzheimer’s disease; and a new marker (Lp-PLA2) for coronary artery disease.
Lawrence M. Prescott, PhD
The authors discuss the factors that influence physician-investigators to prescribe study drugs sooner and more often than physicians who are not involved in clinical trials.
Mark H. Corrigan, MD, and Harold E. Glass, PhD


David B. Nash, MD, MBA, summarizes a 10-point strategy for moving the health care system in the right direction.
David B. Nash, MD, MBA
Prescription: Washington
Stephen Barlas uncovers some of the problems behind the 2004 flu vaccine shortage and suggests ways to prevent vaccine contamination.
Stephen Barlas
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses ways to avoid errors by helping patients understand health information relating to their prescriptions and by helping them feel involved in their health care.
Matthew Grissinger, RPh, FASCP
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
Drs. Vilme, Edwards, and McPherson-Baker review atazanavir for the treatment of HIV-1 infection.
Marie Vilme, PharmD, Deidree Edwards, PharmD, and Shvawn McPherson-Baker, PharmD, MPH, BCPS